US 12,246,005 B2
5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
Jason Gray, Oxford (GB)
Assigned to Beckley Psytech Limited, Oxford (GB)
Filed by Beckley Psytech Limited, Oxford (GB)
Filed on Mar. 15, 2024, as Appl. No. 18/607,093.
Application 18/607,093 is a continuation in part of application No. 18/229,041, filed on Aug. 1, 2023, granted, now 11,980,605.
Claims priority of application No. 2308830 (GB), filed on Jun. 13, 2023; application No. 2314993 (GB), filed on Sep. 29, 2023; application No. 2315176 (GB), filed on Oct. 3, 2023; application No. 2316902 (GB), filed on Nov. 3, 2023; and application No. 2400703 (GB), filed on Jan. 18, 2024.
Prior Publication US 2024/0415811 A1, Dec. 19, 2024
Int. Cl. A61K 31/4045 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/19 (2006.01); A61M 15/08 (2006.01)
CPC A61K 31/4045 (2013.01) [A61K 9/0043 (2013.01); A61K 9/1611 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 9/19 (2013.01); A61M 15/08 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A dry blended free-flowing dry powder pharmaceutical formulation comprising 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), or a pharmaceutically acceptable salt thereof, and silicon dioxide.